ABSTRACT
AIM: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban. METHODS: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012-December 2013 and January 2014-January 2017). RESULTS: 211 patients (mean age 76.7 ± 9.2 years; CHA2DS2-VASc 3.8 ± 1.5; HAS-BLED 2.0 ± 0.8.) were included. Age and bleeding risk were higher in those subjects in which the prescription started earlier. Rates of stroke/TIA, major bleeding and intracranial hemorrhage were 2.3/4.2/0.6 events/100 patient-years, respectively. CONCLUSION: Although, the initial prescription of rivaroxaban was mainly performed in very elderly patients and/or with a higher bleeding risk, this has been extended to the overall nonvalvular atrial fibrillation population.
Subject(s)
Atrial Fibrillation/drug therapy , Factor Xa Inhibitors/therapeutic use , Hemorrhage/epidemiology , Rivaroxaban/therapeutic use , Stroke/prevention & control , Age Factors , Aged , Aged, 80 and over , Atrial Fibrillation/complications , Female , Humans , Male , Patient Selection , Practice Patterns, Physicians' , Retrospective Studies , Stroke/etiology , Treatment OutcomeSubject(s)
Epstein-Barr Virus Infections/diagnosis , Pancreatitis/virology , Acute Disease , Adolescent , Humans , MaleABSTRACT
No disponible
